Evidence map›Paper›PMID 36349112›Full record

ArticleChemical science2022

Automated stopped-flow library synthesis for rapid optimisation and machine learning directed experimentation.

Claudio Avila, Carlo Cassani, Thierry Kogej, Javier Mazuela, Sunil Sarda, Adam D Clayton, Michael Kossenjans, Clive P Green, Richard A Bourne

Abstract read
In one paragraph

Article in Chemical science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Claudio AvilaSample Management, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca Cambridge CB4 0WG UK Claudio.avila@science.cl R.A.Bourne@leeds.ac.uk.ORCID https://orcid.org/0000-0002-5691-6814
Carlo CassaniResearch and Early Development, Medicinal Chemistry Respiratory & Immunology Göteborg Sweden.
Thierry KogejMolecularAI, Discovery Sciences, R&D, AstraZeneca Göteborg Sweden.
Javier MazuelaMolecularAI, Discovery Sciences, R&D, AstraZeneca Göteborg Sweden.
Sunil SardaSample Management, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca Cambridge CB4 0WG UK Claudio.avila@science.cl R.A.Bourne@leeds.ac.uk.ORCID https://orcid.org/0000-0002-1347-0904
Adam D ClaytonInstitute of Process Research and Development, School of Chemistry and School of Chemical and Process Engineering, University of Leeds Leeds LS2 9JT UK.ORCID https://orcid.org/0000-0002-4634-8008
Michael KossenjansResearch and Early Development, Medicinal Chemistry Respiratory & Immunology Göteborg Sweden.
Clive P GreenSample Management, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca Cambridge CB4 0WG UK Claudio.avila@science.cl R.A.Bourne@leeds.ac.uk.
Richard A BourneInstitute of Process Research and Development, School of Chemistry and School of Chemical and Process Engineering, University of Leeds Leeds LS2 9JT UK.ORCID https://orcid.org/0000-0001-7107-6297

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For the discovery of new candidate molecules in the pharmaceutical industry, library synthesis is a critical step, in which library size, diversity, and time to synthesise are fundamental. In this work we propose stopped-flow synthesis as an intermediate alternative to traditional batch and flow chemistry approaches, suited for small molecule pharmaceutical discovery. This method exploits the advantages of both techniques enabling automated experimentation with access to high pressures and temperatures; flexibility of reaction times, with minimal use of reagents (μmol scale per reaction). In this study, we integrate a stopped-flow reactor into a high-throughput continuous platform designed for the synthesis of combinatory libraries with at-line reaction analysis. This approach allowed ∼900 reactions to be conducted in an accelerated timeframe (192 hours). The stopped flow approach used ∼10% of the reactants and solvents compared to a fully continuous approach. This methodology demonstrates a significantly improved synthesis success rate of smaller libraries by simplifying the implementation of cross-reaction optimisation strategies. The experimental datasets were used to train a feed-forward neural network (FFNN) model providing a framework to guide further experiments, which showed good model predictability and success when tested against an external set with fewer experiments. As a result, this work demonstrates that combining experimental automation with machine learning strategies can deliver optimised analyses and enhanced predictions, enabling more efficient drug discovery investigations across the design, make, test and analysis (DMTA) cycle.

Identifiers

PMID36349112
PMCPMC9601405

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.